An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.
Alzheimers Dement
; 19(4): 1204-1215, 2023 04.
Article
em En
| MEDLINE
| ID: mdl-35950735
ABSTRACT
INTRODUCTION:
There is a great need for fully automated plasma assays that can measure amyloid beta (Aß) pathology and predict future Alzheimer's disease (AD) dementia.METHODS:
Two cohorts (n = 920) were examined Panel A+ (n = 32 cognitively unimpaired [CU], n = 106 mild cognitive impairment [MCI], and n = 89 AD) and BioFINDER-1 (n = 461 CU, n = 232 MCI). Plasma Aß42/Aß40, phosphorylated tau (p-tau)181, two p-tau217 variants, ApoE4 protein, neurofilament light, and GFAP were measured using Elecsys prototype immunoassays.RESULTS:
The best biomarker for discriminating Aß-positive versus Aß-negative participants was Aß42/Aß40 (are under the curve [AUC] 0.83-0.87). Combining Aß42/Aß40, p-tau181, and ApoE4 improved the AUCs significantly (0.90 to 0.93; P< 0.01). Adding additional biomarkers had marginal effects (ΔAUC ≤0.01). In BioFINDER, p-tau181, p-tau217, and ApoE4 predicted AD dementia within 6 years in CU (AUC 0.88) and p-tau181, p-tau217, and Aß42/Aß40 in MCI (AUC 0.87).DISCUSSION:
The high accuracies for Aß pathology and future AD dementia using fully automated instruments are promising for implementing plasma biomarkers in clinical trials and clinical routine.Palavras-chave
Alzheimer's disease; Elecsys; amyloid beta; apolipoprotein E; area under the curve; blood; cerebrospinal fluid; clinical practice; cognitively unimpaired; diagnostics; fully automated instruments; glial fibrillary acidic protein; immunoassays; implementation; mild cognitive impairment; neurofilament light; phosphorylated tau; plasma; prediction; prognostics
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Alzheimer
/
Disfunção Cognitiva
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article